We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up.
Diabetes Care 2021 March
OBJECTIVE: To analyze safety and efficacy of the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system in patients with type 1 diabetes in real-world conditions.
RESEARCH DESIGN AND METHODS: After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA1c over 6 months.
RESULTS: The mean (SD; range) age of patients was 43 (13.8; 25-72) years. At baseline, the mean HbA1c and TIR 70-180 mg/dL were, respectively, 7.9% (0.93; 5.6-8.5%) [63 mmol/mol (10; 38-69 mmol/mol)] and 53% (16.4; 21-85%). One patient stopped using the system after 2 months. At 6 months, the mean HbA1c decreased to 7.1% [54 mmol/mol] ( P < 0.001) and TIR 70-180 mg/dL increased to 69.7% ( P < 0.0001). TIR <70 mg/dL decreased from 2.4 to 1.3% ( P = 0.03), and TIR <54 mg/dL decreased from 0.32 to 0.24% ( P = 0.42). No serious adverse event was reported during the study.
CONCLUSIONS: The ability of the DBLG1 system to significantly improve glycemic control in real-world conditions, without serious adverse events, was confirmed in this follow-up study.
RESEARCH DESIGN AND METHODS: After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA1c over 6 months.
RESULTS: The mean (SD; range) age of patients was 43 (13.8; 25-72) years. At baseline, the mean HbA1c and TIR 70-180 mg/dL were, respectively, 7.9% (0.93; 5.6-8.5%) [63 mmol/mol (10; 38-69 mmol/mol)] and 53% (16.4; 21-85%). One patient stopped using the system after 2 months. At 6 months, the mean HbA1c decreased to 7.1% [54 mmol/mol] ( P < 0.001) and TIR 70-180 mg/dL increased to 69.7% ( P < 0.0001). TIR <70 mg/dL decreased from 2.4 to 1.3% ( P = 0.03), and TIR <54 mg/dL decreased from 0.32 to 0.24% ( P = 0.42). No serious adverse event was reported during the study.
CONCLUSIONS: The ability of the DBLG1 system to significantly improve glycemic control in real-world conditions, without serious adverse events, was confirmed in this follow-up study.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app